메뉴 건너뛰기




Volumn 6, Issue 2, 2011, Pages 365-371

Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the united states: Real-world considerations for maintenance therapy

Author keywords

Insurance; Maintenance chemotherapy; Metastatic; Non small cell lung cancer; Practice patterns; Radiation therapy; Second line chemotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

EID: 79551532783     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181fff142     Document Type: Article
Times cited : (41)

References (22)
  • 1
    • 78049401119 scopus 로고    scopus 로고
    • Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC)
    • abstr 7506
    • Belani CP, Waterhouse DM, Ghazal H, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28: abstr 7506.
    • (2010) J. Clin. Oncol. , vol.28
    • Belani, C.P.1    Waterhouse, D.M.2    Ghazal, H.3
  • 2
    • 77953541527 scopus 로고    scopus 로고
    • Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
    • Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
    • (2010) Lancet Oncol. , vol.11 , pp. 521-529
    • Cappuzzo, F.1    Ciuleanu, T.2    Stelmakh, L.3
  • 3
    • 75649135772 scopus 로고    scopus 로고
    • Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: Results from the phase III SATURN study
    • abstract A2.1
    • Cappuzzo F, Coudert BP, Wierzbicki R, et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. J Thorac Oncol 2009;4: S289 (abstract A2.1).
    • (2009) J. Thorac. Oncol. , vol.4
    • Cappuzzo, F.1    Coudert, B.P.2    Wierzbicki, R.3
  • 4
    • 59149092945 scopus 로고    scopus 로고
    • Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
    • Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598.
    • (2009) J. Clin. Oncol. , vol.27 , pp. 591-598
    • Fidias, P.M.1    Dakhil, S.R.2    Lyss, A.P.3
  • 5
    • 77957042719 scopus 로고    scopus 로고
    • Maintenance with either gemcitabine of erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study
    • abstr 7507
    • Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine of erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010;28: abstr 7507.
    • (2010) J. Clin. Oncol. , vol.28
    • Perol, M.1    Chouaid, C.2    Milleron, B.J.3
  • 6
    • 34247882769 scopus 로고    scopus 로고
    • Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: A review of the literature
    • Grossi F, Aita M, Follador A, et al. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007;12:451-464.
    • (2007) Oncologist , vol.12 , pp. 451-464
    • Grossi, F.1    Aita, M.2    Follador, A.3
  • 7
    • 0034069620 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    • Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
    • (2000) J. Clin. Oncol. , vol.18 , pp. 2095-2103
    • Shepherd, F.A.1    Dancey, J.2    Ramlau, R.3
  • 8
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
    • (2004) J. Clin. Oncol. , vol.22 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3
  • 10
    • 70350225538 scopus 로고    scopus 로고
    • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study
    • Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
    • (2009) Lancet , vol.374 , pp. 1432-1440
    • Ciuleanu, T.1    Brodowicz, T.2    Zielinski, C.3
  • 11
    • 77950975446 scopus 로고    scopus 로고
    • Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced nonsmall cell lung cancer? Implications for selection of patients for maintenance therapy
    • Sun JM, Park JO, Won YW, et al. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced nonsmall cell lung cancer? Implications for selection of patients for maintenance therapy. J Thorac Oncol 2010;5:540-545.
    • (2010) J. Thorac. Oncol. , vol.5 , pp. 540-545
    • Sun, J.M.1    Park, J.O.2    Won, Y.W.3
  • 12
    • 0037050354 scopus 로고    scopus 로고
    • Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
    • Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
    • (2002) N. Engl. J. Med. , vol.346 , pp. 85-91
    • Noda, K.1    Nishiwaki, Y.2    Kawahara, M.3
  • 13
    • 33646447066 scopus 로고    scopus 로고
    • Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
    • Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043.
    • (2006) J. Clin. Oncol. , vol.24 , pp. 2038-2043
    • Hanna, N.1    Bunn Jr., P.A.2    Langer, C.3
  • 14
    • 65349116059 scopus 로고    scopus 로고
    • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An openlabel randomised phase III trial
    • Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an openlabel randomised phase III trial. Lancet 2009;373:1525-1531.
    • (2009) Lancet , vol.373 , pp. 1525-1531
    • Pirker, R.1    Pereira, J.R.2    Szczesna, A.3
  • 15
    • 77955092100 scopus 로고    scopus 로고
    • Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era
    • Ahn MJ, Lee J, Park YH, et al. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J Thorac Oncol 2010;5:1185-1196.
    • (2010) J. Thorac. Oncol. , vol.5 , pp. 1185-1196
    • Ahn, M.J.1    Lee, J.2    Park, Y.H.3
  • 16
    • 77954423520 scopus 로고    scopus 로고
    • Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: A collaborative epidemiologic study of the national hospital organization study group for lung cancer (NHSGLC) in Japan and a Southern California regional cancer registry databases
    • Kawaguchi T, Matsumura A, Fukai S, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010;5:1001-1010.
    • (2010) J. Thorac. Oncol. , vol.5 , pp. 1001-1010
    • Kawaguchi, T.1    Matsumura, A.2    Fukai, S.3
  • 17
    • 85030590584 scopus 로고    scopus 로고
    • Dallas County, TX. Available at:, Accessed June 16, 2010
    • U. S. Census State and County Quick Facts: Dallas County, TX. Available at: http://quickfacts.census.gov/qfd/states/48/48113.html. Accessed June 16, 2010.
    • U. S. Census State and County Quick Facts
  • 18
    • 77958199124 scopus 로고    scopus 로고
    • Looking beyond surveillance, epidemiology, and end results: Patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population
    • Rasco DW, Yan J, Xie Y, et al. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010;5:1529-1535.
    • (2010) J. Thorac. Oncol. , vol.5 , pp. 1529-1535
    • Rasco, D.W.1    Yan, J.2    Xie, Y.3
  • 19
    • 33749077728 scopus 로고    scopus 로고
    • Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
    • Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-4411.
    • (2006) J. Clin. Oncol. , vol.24 , pp. 4405-4411
    • Weiss, G.J.1    Langer, C.2    Rosell, R.3
  • 20
    • 1642575171 scopus 로고    scopus 로고
    • Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial
    • Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004;43:183-194.
    • (2004) Lung Cancer , vol.43 , pp. 183-194
    • Dancey, J.1    Shepherd, F.A.2    Gralla, R.J.3    Kim, Y.S.4
  • 21
    • 33847641797 scopus 로고    scopus 로고
    • The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer
    • Weiss GJ, Rosell R, Fossella F, et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:453-460.
    • (2007) Ann. Oncol. , vol.18 , pp. 453-460
    • Weiss, G.J.1    Rosell, R.2    Fossella, F.3
  • 22
    • 77955097091 scopus 로고    scopus 로고
    • Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer
    • Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010;5:1263-1272.
    • (2010) J. Thorac. Oncol. , vol.5 , pp. 1263-1272
    • Klein, R.1    Wielage, R.2    Muehlenbein, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.